First Investigator Meeting for CB-103-C-101

First Investigator Meeting for Cellestia’s CB-103-C-101 first-in-human study with CB-103 (Barcelona, September 19th 2017).

Management Team and Scientific Advisory Board extension

Cellestia Enters Clinical Development for its Lead Compound CB-103